<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="150">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 16, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05159193</url>
  </required_header>
  <id_info>
    <org_study_id>CSPC-DMS-BC-K07</org_study_id>
    <nct_id>NCT05159193</nct_id>
  </id_info>
  <brief_title>Neoadjuvant Treatment Pegylated Liposomal Doxorubicin Plus Cyclophosphamide Sequential Docetaxel Plus Trastuzumab and Pertuzumab Versus Docetaxel Plus Carboplatin Combined With Trastuzumab and Pertuzumab in HER-2 Positive Breast Cancer</brief_title>
  <official_title>A Multicentre, Open-label, Randomised Trial of Neoadjuvant Pegylated Liposomal Doxorubicin Plus Cyclophosphamide Sequential Docetaxel Plus Trastuzumab and Pertuzumab Versus Docetaxel Plus Carboplatin Combined With Trastuzumab and Pertuzumab in HER-2 Positive Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>CSPC Ouyi Pharmaceutical Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multicenter, open label, non-inferiority, randomized controlled clinical study.&#xD;
&#xD;
      The aim of this study is to evaluate the efficacy and safety of a pegylated liposomal&#xD;
      doxorubicin + cyclophosphamide followed by docetaxel plus trastuzumab and pertuzumab (PLD + C&#xD;
      + HP followed by THP) regimen compared with a docetaxel + carboplatin plus trastuzumab and&#xD;
      pertuzumab (TCbHP) regimen in the neoadjuvant treatment of HER-2-positive breast cancer.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">December 2021</start_date>
  <completion_date type="Anticipated">January 2028</completion_date>
  <primary_completion_date type="Anticipated">October 2024</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pathological complete response (pCR) rate</measure>
    <time_frame>Within 2 to 5 weeks after completion of neoadjuvant therapy</time_frame>
    <description>The percentage of participants without residual invasive cancer (ypT0/Tis ypN0 in the current AJCC staging system) when the complete resected breast specimen and all sampled regional lymph nodes were evaluated with hematoxylin and eosin staining after completion of systemic neoadjuvant therapy.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Objective response rate (ORR) at the end of neoadjuvant chemotherapy</measure>
    <time_frame>After the last dose to before surgery or within 21 days</time_frame>
    <description>The number of participants who achieved complete response and partial response at the end of neoadjuvant chemotherapy as a percentage of the overall evaluable participants.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>5-year disease-free survival (DFS) rate</measure>
    <time_frame>5 years</time_frame>
    <description>DFS is defined as the time from randomization to tumor recurrence or death from any cause. 5-year DFS rate is the percentage of participants with DFS from enrollment through 5 years.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Breast conservation rate at surgery</measure>
    <time_frame>Within 2 to 5 weeks after completion of neoadjuvant therapy</time_frame>
    <description>Percentage of participants receiving breast-conserving surgery after neoadjuvant therapy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with treatment-related adverse events as assessed by NCI-CTCAE V5.0, including overall and Grade 3/4 adverse events.</measure>
    <time_frame>5 years</time_frame>
    <description>Number of participants with treatment-related adverse events as assessed by NCI-CTCAE V5.0, including overall and Grade 3/4 adverse events.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants with dose reductions of chemotherapy due to Grade 3/4 adverse events as assessed by NCI-CTCAE V5.0</measure>
    <time_frame>1 year</time_frame>
    <description>Percentage of Participants with dose reductions of chemotherapy due to Grade 3/4 adverse events as assessed by NCI-CTCAE V5.0</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants with chemotherapy delay due to Grade 3/4 adverse events as assessed by NCI-CTCAE V5.0</measure>
    <time_frame>1 year</time_frame>
    <description>Percentage of Participants with chemotherapy delay due to Grade 3/4 adverse events as assessed by NCI-CTCAE V5.0</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relative dose intensity (RDI)</measure>
    <time_frame>1 year</time_frame>
    <description>RDI=actual dose intensity* / standard dose intensity# actual dose intensity* = drug standard dose (mg/m^2) / weeks of administration per cycle (week) standard dose intensity# = actual standard dose (mg/m^2) / actual dosing weeks (week)</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Subgroup analysis of pathological complete response (pCR) rates based on clinically relevant baseline characteristics</measure>
    <time_frame>Within 2 to 5 weeks after completion of neoadjuvant therapy</time_frame>
    <description>Subgroup analysis of pathological complete response (pCR) rates based on clinically relevant baseline characteristics</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">372</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>PLD + C + HP followed by THP</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>pegylated liposomal doxorubicin (PLD) 30 mg/m^2, i.v., d1 + cyclophosphamide (C) 600 mg/m^2, i.v., d1 + trastuzumab (H) 8 mg/kg loading dose, 6 mg/kg maintenance doses, i.v., d1 + pertuzumab (P) 840 mg loading dose, 420 mg maintenance doses, i.v., d1 followed by docetaxel (T) 90~100 mg/m^2, i.v., d1 + trastuzumab (H) 6 mg/kg, i.v., d1 + pertuzumab (P) 420 mg, i.v., d1 q3w, for 4 cycles. After neoadjuvant therapy, patients are required to receive a total of 1 year of treatment with trastuzumab (6mg/kg) combined with pertuzumab (420mg), i.v., d1, q3w, regardless of surgery.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>TCbHP</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>docetaxel (T) 75 mg/m^2, i.v., d1 + carboplatin (Cb) AUC 6, i.v., d1 + trastuzumab (H) 8 mg/kg loading dose, 6 mg/kg maintenance doses, i.v., d1 + pertuzumab (P) 840 mg loading dose, 420 mg maintenance doses, i.v., d1 q3w, for 6 cycles. After neoadjuvant therapy, patients are required to receive a total of 1 year of treatment with trastuzumab (6mg/kg) combined with pertuzumab (420mg), i.v., d1, q3w, regardless of surgery.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>pegylated liposomal doxorubicin (PLD)</intervention_name>
    <description>pegylated liposomal doxorubicin (PLD) 30 mg/m^2, i.v., d1, q3w</description>
    <arm_group_label>PLD + C + HP followed by THP</arm_group_label>
    <other_name>duomeisu</other_name>
    <other_name>Doxorubicin Hydrochloride Liposome Injection</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cyclophosphamide (C)</intervention_name>
    <description>cyclophosphamide (C) 600 mg/m^2, i.v., d1, q3w</description>
    <arm_group_label>PLD + C + HP followed by THP</arm_group_label>
    <other_name>huanlinxianan</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>trastuzumab (H)</intervention_name>
    <description>trastuzumab (H) 8 mg/kg loading dose, 6 mg/kg maintenance doses, i.v., d1, q3w</description>
    <arm_group_label>PLD + C + HP followed by THP</arm_group_label>
    <other_name>qutuozhudankang</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>pertuzumab (P)</intervention_name>
    <description>pertuzumab (P) 840 mg loading dose, 420 mg maintenance doses, i.v., d1, q3w</description>
    <arm_group_label>PLD + C + HP followed by THP</arm_group_label>
    <other_name>patuozhudankang</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>docetaxel (T)</intervention_name>
    <description>docetaxel (T) 90~100 mg/m^2, i.v., d1, q3w</description>
    <arm_group_label>PLD + C + HP followed by THP</arm_group_label>
    <other_name>duoxitasai</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>docetaxel (T)</intervention_name>
    <description>docetaxel (T) 75 mg/m^2, i.v., d1, q3w</description>
    <arm_group_label>TCbHP</arm_group_label>
    <other_name>duoxitasai</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>carboplatin (Cb)</intervention_name>
    <description>carboplatin (Cb) AUC 6, i.v., d1, q3w</description>
    <arm_group_label>TCbHP</arm_group_label>
    <other_name>kabo</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>trastuzumab (H)</intervention_name>
    <description>trastuzumab (H) 8 mg/kg loading dose, 6 mg/kg maintenance doses, i.v., d1, q3w</description>
    <arm_group_label>TCbHP</arm_group_label>
    <other_name>qutuozhudankang</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>pertuzumab (P)</intervention_name>
    <description>pertuzumab (P) 840 mg loading dose, 420 mg maintenance doses, i.v., d1, q3w</description>
    <arm_group_label>TCbHP</arm_group_label>
    <other_name>patuozhudankang</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Female patients aged from 18 to 70 years old;&#xD;
&#xD;
          2. Histologically confirmed as invasive breast cancer and without previous treatment.;&#xD;
&#xD;
          3. HER-2 Positive (defined by IHC 3+ or ISH positive);&#xD;
&#xD;
          4. Tumor &gt; 2cm;&#xD;
&#xD;
          5. Biopsy pathology (FNAB or CNB) diagnosed regional lymph node metastasis within 28 days&#xD;
             prior to randomization;&#xD;
&#xD;
          6. Participants must have at least one measurable disease according to RECIST 1.1.&#xD;
&#xD;
          7. Participants with multifocal tumors (more than one tumor confined to the same quadrant&#xD;
             as the primary tumor) are eligible provided all discrete lesions are sampled and&#xD;
             centrally confirmed as HER2 positive.&#xD;
&#xD;
          8. Operable breast cancer with cT2-cT4/cN1-cN3/cM0, according to the AJCC tumor staging&#xD;
             manual (8th Edition).&#xD;
&#xD;
          9. The HR(ER and PR) status of the primary tumor and the expression level of Ki-67 are&#xD;
             clear.&#xD;
&#xD;
         10. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1;&#xD;
&#xD;
         11. LVEF ≥ 55%;&#xD;
&#xD;
         12. Brain natriuretic peptide (BNP) (or N-terminal pro brain natriuretic peptide (NT&#xD;
             proBNP)) and cardiac troponin assays were within normal values.&#xD;
&#xD;
         13. Alanine aminotransferase (ALT), aspartate aminotransferase (AST), alkaline phosphatase&#xD;
             (ALP) and serum total bilirubin are all ≤2 ULN. Serum creatinine ≤ 1.5 ULN.&#xD;
&#xD;
         14. Bone marrow function: white blood cell counts ≥ 3.0x10^9/L, absolute neutrophil counts&#xD;
             (ANC) ≥ 1.5x10^9/L, platelets ≥ 100x10^9/L, hemoglobin ≥ 90g/L;&#xD;
&#xD;
         15. Participants had good compliance with the planned treatment and follow-up, understood&#xD;
             the study procedures of this study, and signed informed consent form.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Breast cancer with distant metastasis;&#xD;
&#xD;
          2. Participants with multiple lesions (in different quadrants) or bilateral breast&#xD;
             cancer;&#xD;
&#xD;
          3. Participants who have received prior anti-cancer therapy for breast cancer except&#xD;
             those participants with a history of breast lobular carcinoma in situ (LCIS) that was&#xD;
             surgically managed or ductal carcinoma in situ (DCIS) treated exclusively with&#xD;
             mastectomy. In case of prior history of LCIS/DCIS, &gt;5 years must have passed from&#xD;
             surgery until diagnosis of current breast cancer;&#xD;
&#xD;
          4. In the past and present, participants with severe cardiac disease or discomfort ,&#xD;
             including but not limited: 1)High-risk uncontrolled arrhythmia, atrial tachycardia&#xD;
             (heart rate &gt; 100/min in resting state), significant ventricular arrhythmia&#xD;
             (ventricular arrhythmia) or higher atrioventricular block (second-degree type 2&#xD;
             [Mobitz 2] atrioventricular block or third-degree atrioventricular block); 2)Angina&#xD;
             pectoris requiring anti-angina medication; 3)Clinically significant valvular heart&#xD;
             disease; 4)ECG showing transmural myocardial infarction; 5)Uncontrolled hypertension&#xD;
             (eg systolic blood pressure &gt; 180mm Hg or diastolic blood pressure &gt; 100mmHg);&#xD;
             6)Myocardial infarction; 7)Congestive heart failure;&#xD;
&#xD;
          5. Participants have the following serious illnesses or medical conditions, including but&#xD;
             not limited: 1)History of serious neurological or psychiatric disorders, including&#xD;
             psychosis, dementia, or epilepsy, that prevent understanding and informed consent;&#xD;
             2)Active uncontrolled infection; 3)Active peptic ulcer, unstable diabetes;&#xD;
&#xD;
          6. A history of other malignancies within the previous 5 years, except for adequately&#xD;
             treated carcinoma in situ of the cervix or basal cell carcinoma of the skin;&#xD;
&#xD;
          7. Treatment with any investigational drug within 28 days prior to randomization;&#xD;
&#xD;
          8. Participants who are known to be allergic to the active or other components of the&#xD;
             study treatment or have contraindications for surgery;&#xD;
&#xD;
          9. Participants who are pregnant, breastfeeding, or refuse to use adequate contraception&#xD;
             prior to study entry and for the duration of study participation;&#xD;
&#xD;
         10. Participants who were judged by the investigator to be unsuitable for this study.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Sunyat-sen Memorial Hospital</name>
      <address>
        <city>Guandong</city>
        <state>Guangdong</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>December 2021</verification_date>
  <study_first_submitted>November 25, 2021</study_first_submitted>
  <study_first_submitted_qc>December 13, 2021</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 16, 2021</study_first_posted>
  <last_update_submitted>December 13, 2021</last_update_submitted>
  <last_update_submitted_qc>December 13, 2021</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Carboplatin</mesh_term>
    <mesh_term>Docetaxel</mesh_term>
    <mesh_term>Doxorubicin</mesh_term>
    <mesh_term>Liposomal doxorubicin</mesh_term>
    <mesh_term>Trastuzumab</mesh_term>
    <mesh_term>Pertuzumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

